Vigonvita Life Sciences Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	102.1	11.83	199.65
Revenue Growth (YoY)	762.88%	-94.07%	-
Cost of Revenue	21.42	8.35	6.01
Gross Profit	80.68	3.49	193.64
Selling, General & Admin	209.27	69.39	52.51
Research & Development	202.5	134.86	131.3
Operating Expenses	414.96	207.15	186.39
Operating Income	-334.28	-203.66	7.25
Interest Expense	-13.36	-16.16	-7.2
Interest & Investment Income	0.66	0.71	1.79
Currency Exchange Gain (Loss)	-2.85	0.24	0.25
Other Non Operating Income (Expenses)	-6.38	1.21	4.34
EBT Excluding Unusual Items	-356.2	-217.67	6.43
Gain (Loss) on Sale of Investments	-0.71	0.22	-
Gain (Loss) on Sale of Assets	-	-0.04	-
Other Unusual Items	-	-0.16	-
Pretax Income	-356.9	-217.64	6.43
Income Tax Expense	0.21	-	-
Earnings From Continuing Operations	-357.11	-217.64	6.43
Minority Interest in Earnings	1.39	6.24	5.66
Net Income	-355.72	-211.4	12.09
Net Income to Common	-355.72	-211.4	12.09
Shares Outstanding (Basic)	153	146	145
Shares Outstanding (Diluted)	153	146	145
Shares Change (YoY)	4.87%	0.69%	-
EPS (Basic)	-2.33	-1.45	0.08
EPS (Diluted)	-2.33	-1.45	0.08
Free Cash Flow	-256.64	-186.53	-56.05
Free Cash Flow Per Share	-1.68	-1.28	-0.39
Gross Margin	79.02%	29.47%	96.99%
Operating Margin	-327.41%	-1721.30%	3.63%
Profit Margin	-348.42%	-1786.71%	6.05%
Free Cash Flow Margin	-251.38%	-1576.46%	-28.07%
EBITDA	-310.27	-183.23	14.12
EBITDA Margin	-	-	7.07%
D&A For EBITDA	24.01	20.44	6.87
EBIT	-334.28	-203.66	7.25
EBIT Margin	-	-	3.63%